Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

intended to overcome the limitations of currently available agents, e.g., by having greater potency, longer cooling duration, or lack of aroma About Senomyx, Inc. (www.senomyx.com)

Senomyx is using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients.  These include modifiers of Sweet and Salt flavors as well as Savory Flavors, Bitter Blockers, and Cooling Agents.  The Company is also engaged in a new effort to discover and develop natural high-potency sweeteners.  Senomyx sells its flavor ingredients directly to flavor companies.  In addition, Senomyx has collaborative agreements with global food, beverage, and ingredient supply companies, some of which are currently marketing products that contain Senomyx's flavor ingredients.  Its corporate socially responsible activities are described on the Senomyx Cares blog at http://www.senomyx-csrblog.com/.  For more information, please visit www.senomyx.com

Forward-Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our projected financial results and anticipated financial condition for 2013 and future periods; the anticipated funding under existing collaboration agreements; the ant
'/>"/>

SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Biotech Ltd. (Nasdaq: SVA ), a leading provider ... today announced that it will release its unaudited financial ... after market close on Wednesday, August 12, 2015. The Company ... 2015, at 8:00 a.m. EDT (Thursday, August 13, 2015 ... Company,s financial results and provide an update on recent ...
(Date:8/3/2015)... GREENVILLE, N.C. , Aug. 3, 2015 /PRNewswire/ ... will unveil its new Fingerprint Molecular Identification™ (FMID) ... Identification,s educational conference in Sacramento, Calif. ... in forensic science, will enable law enforcement agents, ... molecular profile of criminal suspects. By ...
(Date:8/3/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic and Dental sectors of healthcare, announced today that ... Canaccord|Genuity Growth Conference in Boston, Massachusetts ... William C. Taylor , President and COO, and ...
(Date:8/3/2015)... WESTWOOD, Mass. , Aug. 3, 2015  Merck ... company for innovative and top-quality high-tech products in the ... together with the US-based company Nano-C, their development and ... field of organic photovoltaics (OPV). Merck KGaA, Darmstadt, ... participate in the growing OPV sector. Novel ...
Breaking Biology Technology:Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results 2ArroGen Previews New Fingerprint Molecular Identification Technology 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4
... (Nasdaq: KNDL ) ("Kendle"), announced today that ... cash tender offer and consent solicitation for any and ... outstanding 3.375% Convertible Senior Notes due 2012 (CUSIP No. ... each $1,000.00 principal amount of Notes validly tendered and ...
... 2011 K-V Pharmaceutical Company (NYSE:  KVa/KVb) announced today ... divest Nesher Pharmaceuticals, Inc., its generics subsidiary, and the ... Inc. for approximately $60 million in cash. The transaction ... KV,s 2012 fiscal year, subject to customary closing conditions. ...
... for cell-based diagnostics and regenerative medicine therapies. However, being ... desired cell type -- such as muscle, skin, blood ... of these technologies. New research presented on June ... Society for Stem Cell Research (ISSCR) shows that systematically ...
Cached Biology Technology:Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 2Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 3Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 4K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 2K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 3K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 4K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 5K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 6K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 7Researchers engineer the environment for stem cell development to control differentiation 2Researchers engineer the environment for stem cell development to control differentiation 3
(Date:7/27/2015)... 27, 2015   Zynx Health ™, the ... improvement solutions, today announced that its ZynxCarebook ... on Android smartphones and tablets. With this expansion, ... can use ZynxCarebook to securely exchange messages and ... care transitions to other care settings, and improve ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/188684 for BEHAVIORAL-DIRECTED ... another new convenient and secure method to make ... innovative payment methods, introduced with its groundbreaking voice-direct ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... Ont., June 21, 2011Researchers at St. Michael,s Hospital have found ... with kidney failure. Cells that help protect blood vessels ... the night than those who undergo standard daytime dialysis in ... This is important for patients with kidney failure, which ...
... Cervical ripening that instigates preterm labor is distinct ... labor, researchers at UT Southwestern Medical Center have found. ... cervical ripening and remodeling is likely just an accelerated ... term ripening is caused primarily by activation of inflammatory ...
... perception that bigger, stronger, faster organisms have a distinct ... in a given community. But new research from ... communities, organisms increase their chances of survival if they ... survive as well, a sort of "survival of the ...
Cached Biology News:New evidence of the benefits of home dialysis for kidney patients 2Researchers find process of cervical ripening differs between term and preterm birth 2Bacteria develop restraint for survival in a rock-paper-scissors community 2
... are well-characterized tissue-specific stem cells that exhibit ... the life-long maintenance of the hematopoietic system. ... adult bone marrow where hematopoiesis is continuously ... in cord blood, fetal liver, adult spleen ...
Anti-TWIK-1 Immunogen: Purified peptide from amino acids 53-69 of human TWIK-1 (Accession number O00180)....
EDG-6 (1)...
RAW; Collected from 8-12 week old sexually mature mice that are free of common parasites; RAW Collected from 8-12 week old sexually mature mice that are free of common parasites....
Biology Products: